Literature DB >> 15231008

Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.

Christian Meier1, Henning W Woitge, Klaus Witte, Björn Lemmer, Markus J Seibel.   

Abstract

UNLABELLED: Bone metabolism follows a seasonal pattern with high bone turnover and bone loss during the winter. In a randomized, open-label 2-year sequential follow-up study of 55 healthy adults, we found that supplementation with oral vitamin D3 and calcium during winter abolished seasonal changes in calciotropic hormones and markers of bone turnover and led to an increase in BMD. Supplementation with oral vitamin D3 and calcium during the winter months seems to counteract the effects of seasonal changes in vitamin D and thus may be beneficial as a primary prevention strategy for age-related bone loss.
INTRODUCTION: Bone metabolism follows a seasonal pattern characterized by high bone turnover and bone loss during winter. We investigated whether wintertime supplementation with oral vitamin D3 and calcium had beneficial effects on the circannual changes in bone turnover and bone mass.
MATERIALS AND METHODS: This prospective study comprised an initial observation period of 12 months ("year 1"), followed by an intervention during parts of year 2. Fifty-five healthy subjects living in southwestern Germany (latitude, 49.5 degrees N) were randomized into two groups: 30 subjects were assigned to the treatment group and received oral cholecalciferol (500 IU/day) and calcium (500 mg/day) during the winter months of year 2 (October-April), while 25 subjects assigned to the control group obtained no supplements. Primary endpoints were changes in calciotropic hormones [serum 25(OH)D, 1,25(OH)2D, and parathyroid hormone], markers of bone formation (serum bone-specific alkaline phosphatase) and of bone resorption (urinary pyridinoline and deoxypyridinoline), and changes in lumbar spine and femoral neck BMD.
RESULTS: Forty-three subjects completed the study. During year 1, calciotropic hormones, markers of bone turnover, and BMD varied by season in both groups. During the winter months of year 1, bone turnover was significantly accelerated, and lumbar spine and femoral BMD declined by 0.3-0.9%. In year 2, seasonal changes in calciotropic hormones and markers of bone turnover were either reversed or abolished in the intervention group while unchanged in the control cohort. In the subjects receiving oral vitamin D3 and calcium, lumbar and femoral BMD increased significantly (lumbar spine: +0.8%, p = 0.04 versus year 1; femoral neck: +0.1%, p = 0.05 versus year 1), whereas controls continued to lose bone (intervention group versus control group: lumbar spine, p = 0.03; femoral neck, p = 0.05).
CONCLUSIONS: Supplementation with oral vitamin D3 and calcium during winter prevents seasonal changes in bone turnover and bone loss in healthy adults. It seems conceivable that annually recurring cycles of low vitamin D and mild secondary hyperparathyroidism during the winter months contributes, at least in part and over many years, to age-related bone loss. Supplementation with low-dose oral vitamin D3 and calcium during winter may be an efficient and inexpensive strategy for the primary prevention of bone loss in northern latitudes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231008     DOI: 10.1359/JBMR.040511

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  46 in total

1.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

Review 2.  Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary).

Authors:  David A Hanley; Ann Cranney; Glenville Jones; Susan J Whiting; William D Leslie
Journal:  CMAJ       Date:  2010-07-12       Impact factor: 8.262

Review 3.  Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada.

Authors:  David A Hanley; Ann Cranney; Glenville Jones; Susan J Whiting; William D Leslie; David E C Cole; Stephanie A Atkinson; Robert G Josse; Sidney Feldman; Gregory A Kline; Cheryl Rosen
Journal:  CMAJ       Date:  2010-07-12       Impact factor: 8.262

4.  Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23.

Authors:  Sherri-Ann M Burnett-Bowie; Benjamin Z Leder; Maria P Henao; Chantel M Baldwin; Douglas L Hayden; Joel S Finkelstein
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-02       Impact factor: 8.237

Review 5.  [Relative value of plain vitamin D and of biologically active vitamin D in the prevention and treatment of osteoporosis].

Authors:  S Scharla
Journal:  Z Rheumatol       Date:  2006-09       Impact factor: 1.372

Review 6.  Hypovitaminosis D in the elderly: from bone to brain.

Authors:  E P Cherniack; H Florez; B A Roos; B R Troen; S Levis
Journal:  J Nutr Health Aging       Date:  2008 Jun-Jul       Impact factor: 4.075

7.  Dietary, lifestyle, and genetic determinants of vitamin D status: a cross-sectional analysis from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Germany study.

Authors:  Tilman Kühn; Rudolf Kaaks; Birgit Teucher; Frank Hirche; Jutta Dierkes; Cornelia Weikert; Verena Katzke; Heiner Boeing; Gabriele I Stangl; Brian Buijsse
Journal:  Eur J Nutr       Date:  2013-09-05       Impact factor: 5.614

Review 8.  Vitamin D and bone health: Epidemiologic studies.

Authors:  Peter R Ebeling
Journal:  Bonekey Rep       Date:  2014-03-05

9.  Prevalence of vitamin D depletion among subjects seeking advice on osteoporosis: a five-year cross-sectional study with public health implications.

Authors:  G Guardia; N Parikh; T Eskridge; E Phillips; G Divine; D Sudhaker Rao
Journal:  Osteoporos Int       Date:  2007-09-18       Impact factor: 4.507

Review 10.  Bone turnover in nutrition-related disorders.

Authors:  Markus J Seibel
Journal:  Wien Med Wochenschr       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.